NO20070790L - Fremgangsmate for a fremstille bisykliske pyrazolylforbindelser - Google Patents

Fremgangsmate for a fremstille bisykliske pyrazolylforbindelser

Info

Publication number
NO20070790L
NO20070790L NO20070790A NO20070790A NO20070790L NO 20070790 L NO20070790 L NO 20070790L NO 20070790 A NO20070790 A NO 20070790A NO 20070790 A NO20070790 A NO 20070790A NO 20070790 L NO20070790 L NO 20070790L
Authority
NO
Norway
Prior art keywords
pyrazolyl compounds
preparing bicyclic
preparing
bicyclic pyrazolyl
compounds
Prior art date
Application number
NO20070790A
Other languages
English (en)
Inventor
Thomas Andrew Brandt
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20070790L publication Critical patent/NO20070790L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives en fremgangsmåte for fremstilling av en forbindelse av formel (1). Forbindelsene har blitt vist å fungere som cannabinoide reseptorhgander og er derfor nyttige i behandling av sykdommer koblet til mediering av cannabinoidreseptorer i dyr.
NO20070790A 2004-09-27 2007-02-09 Fremgangsmate for a fremstille bisykliske pyrazolylforbindelser NO20070790L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61361304P 2004-09-27 2004-09-27
PCT/IB2005/003027 WO2006035310A2 (en) 2004-09-27 2005-09-15 Process for preparing bicyclic pyrazolyl compounds

Publications (1)

Publication Number Publication Date
NO20070790L true NO20070790L (no) 2007-03-08

Family

ID=36010942

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070790A NO20070790L (no) 2004-09-27 2007-02-09 Fremgangsmate for a fremstille bisykliske pyrazolylforbindelser

Country Status (16)

Country Link
US (1) US20070260056A1 (no)
EP (1) EP1797041A2 (no)
JP (1) JP2008514584A (no)
KR (1) KR20070051921A (no)
CN (1) CN101027285A (no)
AR (1) AR050954A1 (no)
AU (1) AU2005288671A1 (no)
BR (1) BRPI0515281A (no)
CA (1) CA2581747A1 (no)
IL (1) IL181721A0 (no)
MX (1) MX2007003586A (no)
NO (1) NO20070790L (no)
NZ (1) NZ553071A (no)
TW (1) TW200626557A (no)
WO (1) WO2006035310A2 (no)
ZA (1) ZA200701279B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US7872006B2 (en) 2005-10-21 2011-01-18 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
JP2005507875A (ja) * 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

Also Published As

Publication number Publication date
WO2006035310A2 (en) 2006-04-06
ZA200701279B (en) 2008-09-25
NZ553071A (en) 2009-07-31
IL181721A0 (en) 2007-07-04
AU2005288671A1 (en) 2006-04-06
WO2006035310A3 (en) 2006-06-01
US20070260056A1 (en) 2007-11-08
TW200626557A (en) 2006-08-01
KR20070051921A (ko) 2007-05-18
JP2008514584A (ja) 2008-05-08
CA2581747A1 (en) 2006-04-06
EP1797041A2 (en) 2007-06-20
BRPI0515281A (pt) 2008-07-15
CN101027285A (zh) 2007-08-29
MX2007003586A (es) 2007-05-21
AR050954A1 (es) 2006-12-06

Similar Documents

Publication Publication Date Title
NO20062618L (no) Bicykliske pyrazolyl og imidazolylforbindelser og andvendelse derav
CA2515596A1 (en) Cannabinoid receptor ligands and uses thereof
TW200503723A (en) Cannabinoid receptor ligands and uses thereof
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
WO2007015999A3 (en) Process for synthesizing a substituted pyrazole
TW200510419A (en) Cannabinoid receptor ligands and uses thereof
ATE402697T1 (de) 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
CY1112011T1 (el) Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
MXPA05013282A (es) Derivados de pirimidina como ligandos del receptor de cannabinoides.
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
NO20051871L (no) Opioidreseptorantagonister
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
ME00004B (me) Derivati pirimidina
RS20050306A (en) Purine compounds and uses thereof as cannabinoid receptor ligands
ATE453620T1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
NO20063132L (no) Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NZ599254A (en) Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
NO20074188L (no) Prosess for fremstilling av montelukast og mellomprodukter for det
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application